Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team

by NASDAQ Market News March 29, 2019

NASDAQ Market News
Click here to email author

Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million

Global Cell Therapy Market, 2018-2019: Companies to Action (C2A) Profiles, Segmented by Tier

Ads